Hey guys I'm a new investor and AT1 is my first real holding....

Hey guys I'm a new investor and AT1 is my first real holding. I'm a uni student with quite decent savings from farm work, I decided to throw 80% of into AT1 after doing some pretty lackluster initial research. I've been holding since SP was at 50 cents but the bulk of my holdings was bought at $0.29. I've read every HC post about it since and always read announcements and any media John Kelly talks in.
From what I understand so far Atomo is doing very well in their production expansion and in their quest of obtaining regulatory approvals for their products but the lack of clear-cut financial information (profit margin on the devices, cost of production etc...) is preventing the SP from moving up - is this the widely accepted reason for AT1's stagnant share price despite what seem to be major goals being kicked every month?
Finally, to potentially more experienced investors, is this a common occurrence with companies in their IPO year? Have any similar biotech stocks performed like this despite steady advances? Is it realistic to see this company's shares trading for $5+ in the next 20 years? It sounds crazy but as far as I am aware there are no competitors so the only income cap is the size of the market for Atomo's product, and it is such a versatile and simple product that the sky is the limit for who AT1 could be selling to a decade from now.
Pretty useless and TMI comment but I'm sick of checking the AT1 HC forum and seeing no new posts so I thought I'd do it myself